T1	Participants 138 193	Patients with acute exacerbations of chronic bronchitis
T2	Participants 347 394	548 patients enrolled, 281 (51%) were evaluable
T3	Participants 491 545	evaluable patients treated with cefdinir and cefprozil
T4	Participants 926 944	evaluable patients
T5	Participants 1102 1224	diarrhoea during therapy was higher for patients treated with cefdinir (17%) than for patients treated with cefprozil (6%)
T6	Participants 1400 1421	treatment of patients
